Knowing stock market today at a glance

Syndax Pharmaceuticals (SNDX) Soars 10.95% on Analyst Optimism

Mover TrackerThursday, Apr 17, 2025 5:39 am ET

1min read

Syndax Pharmaceuticals Inc. (SNDX) shares surged 10.95% in pre-market trading on April 17, 2025, reflecting a significant boost in investor confidence.

Syndax Pharmaceuticals, a biotechnology company focused on cancer treatments, recently reported its fourth-quarter financial results. The company posted a loss and missed revenue estimates, which could have contributed to the recent volatility in its stock price. Despite these challenges, the company's stock has shown resilience, indicating that investors remain optimistic about its long-term prospects.

Syndax Pharmaceuticals has been actively engaging with financial analysts and investors. The company's management recently participated in a conference call with jpmorgan, and its price target was raised to $41 from $39 by an analyst. Additionally, the company's price target was lowered to $19 from $33 at Barclays, suggesting a mixed outlook among analysts. These interactions and adjustments in price targets reflect the ongoing evaluation of Syndax's potential and the dynamic nature of the biotech sector.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.